title: A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
abstract: OBJECTIVE
  Glucagon-like peptides receptor agonists are currently approved as anti-obesity agents, yet the experience with their use in polycystic ovarian syndromes (PCOS)-related obesity and insulin resistance is still limited.
  
  
  METHODS
  We examined the effects of liraglutide on obesity, insulin resistance, and androgen levels in PCOS through a meta-analysis.
  
  
  RESULTS
  Seven RCTs where women with PCOS were treated with liraglutide were identified. The variables that were examined before and after a 90-day treatment included waist circumference, body mass index (BMI), fasting insulin concentrations, insulin resistance using homeostatic model (HOMA-IR), serum testosterone, and sex hormone-binding globulin (SHBG). The analysis included 178 women. Only 172 patients had post-treatment measurements. While BMI significantly dropped by -1.65 (0.72-2.58) Kg/m(2) after 3 months treatment with liraglutide, waist circumference did not change significantly. Similarly, fasting insulin levels, insulin sensitivity, and SHBG did not change significantly. However, serum testosterone decreased by 0.29 nmol/L in 88 women (P = 0.0003).
  
  
  CONCLUSIONS
  In a limited number of the women with PCOS, BMI and serum testosterone are only variables that significantly decrease after 3 months of treatment with GLP-1 receptor agonists. Larger sample size studies with longer durations of treatment may be required to examine potential benefits of these medications in improving insulin sensitivity.
authors.affiliation: Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, IRAN.
authors.forename: Mitra
authors.initials: M
authors.lastname: Niafar
authors.affiliation: Deptartment of Anesthesiology, University at Buffalo, Buffalo, NY, 14214, USA.
authors.forename: Leili
authors.initials: L
authors.lastname: Pourafkari
authors.affiliation: Deptartment of Anesthesiology, University at Buffalo, Buffalo, NY, 14214, USA.
authors.forename: Jahan
authors.initials: J
authors.lastname: Porhomayon
authors.affiliation: Deptartment of Anesthesiology, University at Buffalo, Buffalo, NY, 14214, USA. nnader@buffalo.edu.
authors.forename: Nader
authors.initials: N
authors.lastname: Nader
mesh_terms: D000328:Adult; D000728:Androgens / Q000097:blood*; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D000069450:Liraglutide / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000378:metabolism*; D009765:Obesity / Q000097:blood / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D000728:Androgens; D007004:Hypoglycemic Agents; D007328:Insulin; D012738:Sex Hormone-Binding Globulin; D000069450:Liraglutide; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: Androgens; Insulin resistance; Obesity; Polycystic ovarian syndrome